Core Insights - Siemens Healthineers showcased numerous innovative products at the sixth China International Import Expo, emphasizing their commitment to healthcare innovation [1][2] - The company has deep roots in the Chinese market, having established a significant presence over the past 30 years, which has contributed to the development of the local healthcare industry [3] Product Innovation - Siemens Healthineers introduced the world's first photon-counting CT, which has received approvals from FDA, CE, and NMPA, marking a revolutionary advancement in CT technology [2] - The photon-counting CT was approved in China in October, significantly reducing the time for market entry through an expedited review process [2] Market Strategy - The company has invested 1 billion RMB to establish a high-end medical equipment R&D and production base in the Greater Bay Area, enhancing its production capacity and R&D resources [4] - Siemens Healthineers operates six production bases in China, with plans for production upgrades at its Wuxi facility to enhance CT component manufacturing [6] Global Contribution - Siemens Healthineers aims to leverage Chinese innovations for global markets, contributing to the global healthcare landscape [5] - The company is building a multi-dimensional innovation ecosystem by integrating local innovations with its global expertise [6]

Core Viewpoint - Siemens Healthineers has launched its first domestic high-end diagnostic device, the Atellica fully automated biochemical immunoassay analyzer, marking a significant step in local innovation and accessibility of high-end diagnostic products in China [1][3]. Group 1: Product Launch and Features - The Atellica fully automated biochemical immunoassay analyzer has officially commenced production at Siemens Healthineers' Shanghai R&D and manufacturing base, representing the first laboratory diagnostic instrument production line in the Asia-Pacific region [3]. - The device adheres to global quality standards and incorporates advanced technologies such as automatic quality control, visual recognition, magnetic track, and temperature and humidity control, enhancing both quality and efficiency [4]. - The analyzer occupies only 6 square meters, meeting the stringent space requirements of emergency laboratories, and provides rapid and efficient testing capabilities crucial for urgent clinical diagnostics [4]. Group 2: Workflow Optimization and Performance - At Peking Union Medical College Hospital, the implementation of the Atellica analyzer resulted in a 9% increase in workload while reducing the P95 turnaround time (TAT) from 96 minutes to 64 minutes, a decrease of 33% [5]. - Sichuan University West China Fourth Hospital reported that the automatic quality control feature reduced the manual steps required from 14 to just 1, while also decreasing the consumption of quality control materials by 20% [5]. Group 3: Clinical Applications and Regulatory Approval - The Atellica analyzer utilizes principles of photometry, potentiometry, and chemiluminescence for qualitative and quantitative detection of analytes in various human samples, including whole blood, serum, plasma, urine, cerebrospinal fluid, and amniotic fluid [8]. - The product received NMPA approval in April of this year, indicating its compliance with local regulatory standards and furthering Siemens Healthineers' "National Intelligence Innovation" strategy in China [8]. Group 4: Strategic Collaboration - Siemens Healthineers and Fosun Diagnostics have announced a strategic partnership to develop a series of localized biochemical reagent solutions based on the Atellica analyzer, covering areas such as liver function, kidney function, myocardial enzymes, and glucose metabolism [9][11]. - The collaboration aims to significantly reduce costs for end-users, shorten product delivery cycles, and enhance user experience while meeting clinical validation standards [11]. - Since 2019, Siemens Healthineers and Fosun Diagnostics have co-developed multiple domestic biochemical reagent solutions, with plans to deepen and expand their strategic cooperation to create more high-value products and services [13][15]. Group 5: Industry Impact - The partnership between Fosun Diagnostics and Siemens Healthineers is expected to promote the upgrade and development of China's in vitro diagnostic industry, enhancing the technical level and market competitiveness of domestic diagnostic products [17].